XANTHOMAS AND HYPERLIPIDEMIA IN A HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILD RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
- 1 March 2002
- journal article
- case report
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 21 (3) , 259-260
- https://doi.org/10.1097/00006454-200203000-00021
Abstract
An 8-year-old perinatally HIV-infected boy developed xanthomas secondary to highly active antiretroviral therapy-induced hyperlipidemia. This is a phenomenon previously not reported in HIV-infected children. The case illustrates the difficulty in managing an emerging complication, extreme hyperlipidemia, in children receiving highly active antiretroviral therapy because of limited pediatric experience with lipid-lowering agents and the likely need for lifelong treatment.Keywords
This publication has 6 references indexed in Scilit:
- Disorders of Glucose Metabolism in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 2000
- Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and LipodystrophyArchives of internal medicine (1960), 2000
- Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease InhibitorsCirculation, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapineAIDS, 1999
- Abnormal body-fat distribution in HIV-1-infected children on antiretroviralsThe Lancet, 1999